KDR and neoplasm: Targeted therapies primarily function by inhibiting angiogenic pathways critical for tumor vascularization, including VEGFR, FGFR, PDGFR, etc. (20–22) Several retrospective studies of targeted therapies in elderly patients have shown that the efficacy and safety of targeted therapies in elderly patients are not significantly different from those in young patients (23–27).